Browsing by Author Wu, Yi-Long

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Showing results 1 to 20 of 35 next >
Issue Date Title Author(s)
9-Jul-2021 Afatinib in EGFR TKI-Naive Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies Passaro, Antonio;de Marinis, Filippo;Tu, Hai-Yan;Laktionov, Konstantin K.;Feng, Jifeng;Poltoratskiy, Artem;Zhao, Jun;Tan, Eng Huat;Gottfried, Maya;Lee, Victor;Kowalski, Dariusz;Yang, Cheng Ta;Srinivasa, B. J.;Clementi, Laura;Jalikop, Tejaswini;Huang, Dennis Chin Lun;Cseh, Agnieszka;Park, Keunchil;Wu, Yi-Long
15-Apr-2020 Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study Lu, Chang;Dong, Xiao-Rong;Zhao, Jun;Zhang, Xu-Chao;Chen, Hua-Jun;Zhou, Qing;Tu, Hai-Yan;Ai, Xing-Hao;Chen, Xiao-Feng;An, Gai-Li;Bai, Jun;Shan, Jin-Lu;Wang, Yi-Na;Yang, Shuan-Ying;Liu, Xiang;Zhuang, Wu;Wu, Hui-Ta;Zhu, Bo;Xia, Xue-Feng;Chen, Rong-Rong;Gu, De-Jian;Xu, Hua-Min;Wu, Yi-Long;Yang, Jin-Ji
Feb-2022 Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm plus non-small-cell lung cancer Zhao, Jun;Bai, Hua;Wang, Xin;Wang, Yuyan;Duan, Jianchun;Chen, Hanxiao;Xue, Zhiyi;Tian, Yahui;Cseh, Agnieszka;Huang, Dennis Chin-Lun;Wu, Yi-Long;Wang, Jie
Mar-2021 Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer Ni, Jun;Huang, Miao;Zhang, Li;Wu, Nan;Bai, Chun-Xue;Chen, Liang-An;Liang, Jun;Liu, Qian;Wang, Jie;Wu, Yi-Long;Zhang, Feng-Chun;Zhang, Shu-Yang;Chen, Chun;Chen, Jun;Fang, Wen-Tao;Gao, Shu-Geng;Hu, Jian;Jiang, Tao;Li, Shan-Qing;Li, He-Cheng;Liao, Yong-De;Liu, Yang;Liu, De-Ruo;Liu, Hong-Xu;Liu, Jian-Yang;Liu, Lun-Xu;Wang, Meng-Zhao;Wang, Chang-Li;Yang, Fan;Yang, Yue;Zhang, Lan-Jun;Zhi, Xiu-Yi;Zhong, Wen-Zhao;Guan, Yu-Zhou;Guo, Xiao-Xiao;He, Chun-Xia;Li, Shao-Lei;Li, Yue;Liang, Nai-Xin;Lu, Fang-Liang;Lv, Chao;Lv, Wei;Si, Xiao-Yan;Tan, Feng-Wei;Wang, Han-Ping;Wang, Jiang-Shan;Yan, Shi;Yang, Hua-Xia;Zhu, Hui-Juan;Zhuang, Jun-Ling;Zhuo, Ming-Lei
2019 Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients Zhang, Xu-Chao;Wang, Jun;Shao, Guo-Guang;Wang, Qun;Qu, Xiaotao;Wang, Bo;Moy, Christopher;Fan, Yue;Albertyn, Zayed;Huang, Xiayu;Zhang, Jingyu;Qiu, Yang;Platero, Suso;Lorenzi, Matthew V.;Zudaire, Enrique;Yang, Jennifer;Cheng, Ying;Xu, Lin;Wu, Yi-Long
2018 A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel Wu, Yi-Long;Wang, Chang-Li;Liao, Mei-Lin;Guan, Zhong-Zhen;Gao, Chen-Yan;Lu, Shun;Zhao, Ming-Fang;Wang, Jie;Liu, Xiao-Qing;Yang, Jin-Ji;Liang, Jun;Mao, Wei-Min;Han, Bao-Hui;Zhang, Xu-Chao;Song, Yong;Feng, Ji-Feng;Ma, Sheng-Lin;Wu, Gang;Zhou, Cai-Cun;Chen, Ke-Neng;Cheng, Ying;He, Yong;Chen, Chun;Wang, Qun;Lin, Ji-Zhen;Zhu, Bo;Liu, Yun-Peng;Hu, Yi;Qiao, Gui-Bin;Zhou, Qing;Song, Qi-Bin;Wu, Nan;Wu, Lin;Huang, Cheng;Fu, Xiao-Long;Xiong, Jian-Ping;Hu, Jie;Hu, Cheng-Ping;Chang, Jian-Hua;Zhao, Qiong;Zhao, Jun;Zhou,
2017 A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel Wu, Yi-Long;Wang, Chang-Li;Sun, Yan;Liao, Mei-Lin;Guan, Zhong-Zhen;Yang, Zhi-Min;Zhou, Qing-Hua;Lu, Shun;Cheng, Ying;Liu, Xiao-Qing;Zhang, Xu-Chao;Zhou, Caicun;Wang, Jie;Zhou, Qing;Song, Yong;Han, Bao-Hui;Ma, Zhi-Yong;Yang, Fan;Wang, Qun;Chuai, Shao-Kun;Shao, Yang;He, Wei;Zhu, Guanshan;Xiong, Lei;Wang, Jian-Jun;Chen, Ke-Neng;Zhang, Li;Mao, Wei-Min;Ma, Sheng-Lin;Feng, Ji-Feng;Yang, Xue-Ning;Xu, Lin;Chen, Gang;Zhao, Jian;Song, Qi-Bin;Shen-Tu, Yang;Qiao, Gui-Bin;Yu, Ding;Yu, Shi-Ying;Hu, Yi;Chen, Ming;Chen, Go
20-May-2021 CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer. Wu, Yi-Long;Zhong, Wenzhao;Chen, Ke-Neng;Chen, Chun;Yang, Fan;Yang, Xue-Ning;Gu, Chundong;Mao, Weimin;Wang, Qun;Qiao, Gui-Bin;Cheng, Ying;Xu, Lin;Wang, Changli;Chen, Mingwei;Yan, Hong-Hong;Liao, Ri-qiang;Zhang, Xuchao;Yang, Jinji;Liu, Si-yang;Zhou, Qing
20-May-2020 CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. Wu, Yi-Long;Zhong, Wenzhao;Wang, Qun;Mao, Weimin;Xu, Song-Tao;Wu, Lin;Chen, Chun;Cheng, Ying;Xu, Lin;Wang, Jun;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhidong;Xu, Shun;Yang, Jin-Ji;Yan, Hong-Hong;Yang, Xue-Ning;Liu, Si-yang;Zhou, Qing
Jan-2020 Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study Zhang, Jia-Tao;Li, Ye;Yan, Li-Xu;Zhu, Zheng-Fei;Dong, Xiao-Rong;Chu, Qian;Wu, Lin;Zhang, Hong-Mei;Xu, Chun-Wei;Lin, Gen;Yu, Zong-Yang;Hu, Jie;Zhu, Bo;Wang, Hui-Juan;Yang, Fan;Song, Zheng-Bo;Han, Zheng-Bo;Li, Meng-Xia;Lin, Jie;Wu, Yi-Long;Wang, Jin-Liang;Zhong, Wen-Zhao
2011 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Zhou, Caicun;Wu, Yi-Long;Chen, Gongyan;Feng, Jifeng;Liu, Xiao-Qing;Wang, Changli;Zhang, Shucai;Wang, Jie;Zhou, Songwen;Ren, Shengxiang;Lu, Shun;Zhang, Li;Hu, Chengping;Hu, Chunhong;Luo, Yi;Chen, Lei;Ye, Ming;Huang, Jianan;Zhi, Xiuyi;Zhang, Yiping;Xiu, Qingyu;Ma, Jun;Zhang, Li;You, Changxuan
2019 Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study Zhong, Wen-Zhao;Chen, Ke-Neng;Chen, Chun;Gu, Chun-Dong;Wang, Jun;Yang, Xue-Ning;Mao, Wei-Min;Wang, Qun;Qiao, Gui-Bin;Cheng, Ying;Xu, Lin;Wang, Chang-Li;Chen, Ming-Wei;Kang, Xiaozheng;Yan, Wanpu;Yan, Hong-Hong;Liao, Ri-Qiang;Yang, Jin-Ji;Zhang, Xu-Chao;Zhou, Qing;Wu, Yi-Long
2017 Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses Mok, Tony S. K.;Kim, Sang-We;Wu, Yi-Long;Nakagawa, Kazuhiko;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You;Atagi, Shinji;Ponce, Santiago;Shi, Xiaojin;Rukazenkov, Yuri;Haddad, Vincent;Thress, Kenneth S.;Soria, Jean-Charles
2015 Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Soria, Jean-Charles;Wu, Yi-Long;Nakagawa, Kazuhiko;Kim, Sang-We;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You;Atagi, Shinji;Ponce, Santiago;Lee, Dae Ho;Liu, Yunpeng;Yoh, Kiyotaka;Zhou, Jian-Ying;Shi, Xiaojin;Webster, Alan;Jiang, Haiyi;Mok, Tony S. K.
2018 Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Zhong, Wen-Zhao;Wang, Qun;Mao, Wei-Min;Xu, Song-Tao;Wu, Lin;Shen, Yi;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Xu, Lin;Wang, Jun;Fei, Ke;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yan, Hong-Hong;Yang, Xue-Ning;Zhou, Qing;Wu, Yi-Long
1-Mar-2021 Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial Zhong, Wen-Zhao;Wang, Qun;Mao, Wei-Min;Xu, Song-Tao;Wu, Lin;Wei, Yu-Cheng;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Yin, Rong;Yang, Fan;Ren, Sheng-Xiang;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yang, Jin-Ji;Yan, Hong-Hong;Yang, Xue-Ning;Liu, Si-Yang;Zhou, Qing;Wu, Yi-Long
2015 Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup Analysis Soria, Jean-Charles;Kim, Sang-We;Wu, Yi-Long;Nakagawa, Kazuhiko;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You;Atagi, Shinji;Ponce, Santiago;Shi, Xiaojin;Taylor, Rosemary;Jiang, Haiyi;Thress, Kenneth;Mok, Tony
Oct-2020 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiothera Zhou, Qing;Chen, Ming;Wu, Gang;Chang, Jian-Hua;Jiang, Ou;Cui, Jiu-Wei;Han, Guang;Lin, Qin;Fang, Jian;Chen, Gong-Yan;Wu, Yi-Long
8-Nov-2021 Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes Liu, Si-Yang;Bao, Hua;Wang, Qun;Mao, Wei-Min;Chen, Yedan;Tong, Xiaoling;Xu, Song-Tao;Wu, Lin;Wei, Yu-Cheng;Liu, Yong-Yu;Chen, Chun;Cheng, Ying;Yin, Rong;Yang, Fan;Ren, Sheng-Xiang;Li, Xiao-Fei;Li, Jian;Huang, Cheng;Liu, Zhi-Dong;Xu, Shun;Chen, Ke-Neng;Xu, Shi-Dong;Liu, Lun-Xu;Yu, Ping;Wang, Bu-Hai;Ma, Hai-Tao;Yan, Hong-Hong;Dong, Song;Zhang, Xu-Chao;Su, Jian;Yang, Jin-Ji;Yang, Xue-Ning;Zhou, Qing;Wu, Xue;Shao, Yang;Zhong, Wen-Zhao;Wu, Yi-Long
20-May-2020 Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC). Desai, Jayesh;Wang, Jie;Zhou, Qing;Zhao, Jun;Deva, Sanjeev;Tan, Wei;Ma, Xiaopeng;Zhang, Yun;Shen, Zhirong;Wu, Xikun;Leaw, Shiangjiin;Wu, Yanjie;Wu, Yi-Long
Showing results 1 to 20 of 35 next >